All Columns articles
View all stories with this category.
-
-
OpinionUK researchers need to know academic freedom is safe from political interference
The UK science secretary’s recent statements are causing alarm in the research community
-
OpinionSlow march of the retrosynthesis robots
Software synthesis suggestions are hampered by biased and incomplete datasets
-
-
OpinionThe PFAS problem in everyone’s back yard
Communities around the world will have to get to grips with a new pollution problem that will cost billions to address
-
-
OpinionThe classic sandwich
Ferrocene turned our understanding of structure and bonding on its head
-
OpinionThe UK has rejoined Horizon Europe, but the delays have been costly
The deal to rejoin the EU’s science programme makes sense for the country and it’s well overdue
-
OpinionResistant to change
Curbing industrial practices that drive antimicrobial resistance needs tighter regulation and enforcement
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
-
OpinionNavigating the literature torrent
It’s humanly impossible to filter and read everything worthwhile – let’s embrace assistance
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
OpinionThe heavy appeal of liquid metals
The shiny and dense fluids offer both ancient mystery and future promise
-
OpinionThe end of chemical warfare
With a final push we might see these terrible weapons disappear from the world in our lifetime
-
OpinionWhiteboards and napkins
How chemical intuition and guesses become the precise numbers of chemistry
-
-
OpinionBringing drug manufacturing back home
Pharmaceutical supply chains are international, complex and opaque. Is there a better way?
-
OpinionReturning to the moon
It’s been a while, but space agencies are starting to plan their trips back to our satellite, with the goal of building semi-permanent bases
-
OpinionRegulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards